Growth Metrics

Acro Biomedical (ACBM) Accumulated Expenses (2021 - 2022)

Acro Biomedical's quarterly Accumulated Expenses came in at $19.8 million in Q1 2022, down 16.52% quarter-over-quarter from $23.8 million in Q4 2021.

Acro Biomedical has reported Accumulated Expenses for 2 years, with the latest figure at $19.8 million in Q1 2022.

  • For the quarter ending Q1 2022, Accumulated Expenses changed N/A year-over-year to $19.8 million; the trailing twelve-month figure through Mar 2022 stood at $19.8 million (changed N/A YoY), and the FY2021 full-year result was $23.8 million, changed N/A from the prior year.
  • Accumulated Expenses for Q1 2022 stood at $19.8 million, down from $23.8 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $23.8 million in Q4 2021, with the low at $18.5 million in Q2 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 EQV Ventures Acquisition 477.69 Mn 477.69 Mn -
2 Berto Acquisition 316.66 Mn 316.66 Mn -
3 Centurion Acquisition 311.94 Mn 311.94 Mn -
4 Churchill Capital Corp IX 311.36 Mn 311.36 Mn -
5 Agriculture & Natural Solutions Acquisition 301.94 Mn 301.94 Mn -
6 Siddhi Acquisition Corp (Cayman Islands) 286.76 Mn 286.76 Mn -
7 Bold Eagle Acquisition 276.06 Mn 276.06 Mn -
8 Cartesian Growth Corp III 270.68 Mn 270.68 Mn -
9 Oyster Enterprises II Acquisition 266.84 Mn 266.84 Mn -
10 Acro Biomedical - - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2022 19.85 Mn
Dec 31, 2021 23.77 Mn
Jun 30, 2021 18.51 Mn